Histocompatibility Antigens Class II
"Histocompatibility Antigens Class II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
| Descriptor ID |
D000949
|
| MeSH Number(s) |
D12.776.395.550.509 D12.776.543.550.440 D23.050.301.500.400 D23.050.705.552.410
|
| Concept/Terms |
Histocompatibility Antigens Class II- Histocompatibility Antigens Class II
- Class II Antigens
- Antigens, Class II
- Class II Histocompatibility Antigens
- Ia-Like Antigens
- Antigens, Ia-Like
- Ia Like Antigens
- IA Antigen
- Antigen, IA
- I-A Antigen
- Antigen, I-A
- Antigens, Immune Response
- Immune Response Antigens
- Immune-Response-Associated Antigens
- Antigens, Immune-Response-Associated
- Immune Response Associated Antigens
- Class II Major Histocompatibility Antigens
- I-A-Antigen
- I A Antigen
- Class II Antigen
- Antigen, Class II
- Ia Antigens
- Antigens, Ia
|
Below are MeSH descriptors whose meaning is more general than "Histocompatibility Antigens Class II".
Below are MeSH descriptors whose meaning is more specific than "Histocompatibility Antigens Class II".
This graph shows the total number of publications written about "Histocompatibility Antigens Class II" by people in this website by year, and whether "Histocompatibility Antigens Class II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1997 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2017 | 11 | 7 | 18 |
| 2018 | 11 | 8 | 19 |
| 2019 | 4 | 1 | 5 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 4 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Histocompatibility Antigens Class II" by people in Profiles.
-
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died. JAMA Neurol. 2021 08 01; 78(8):948-960.
-
Individual HLA-A, -B, -C, and -DRB1 Genotypes Are No Major Factors Which Determine COVID-19 Severity. Front Immunol. 2021; 12:698193.
-
Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level. Front Immunol. 2021; 12:669357.
-
Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nat Commun. 2021 07 05; 12(1):4117.
-
Landscape and selection of vaccine epitopes in SARS-CoV-2. Genome Med. 2021 06 14; 13(1):101.
-
Can molecular mimicry explain the cytokine storm of SARS-CoV-2?: An in silico approach. J Med Virol. 2021 Sep; 93(9):5350-5357.
-
Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics. Cell Rep. 2021 06 29; 35(13):109305.
-
Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. Cell Rep. 2021 05 25; 35(8):109179.
-
Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein. PLoS One. 2021; 16(3):e0248061.
-
Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers. Vaccine. 2021 04 08; 39(15):2110-2116.